For DSS, patients with higher TGIF2 expression had worse DSS in subgroups such as age >60, age ≤60, male, female, race (White), WHO grade (G3), 1p/19q codeletion status (non-codel), histological type (astrocytoma), primary therapy outcome (PD) and primary therapy outcome (SD) (Supplementary Figures S1A–J). Here, TGIF2 is linked to astrocytoma (excluding glioblastoma).